Oxadiazoles useful in the treatment of senile dementia
申请人:Merck, Sharp & Dohme, Ltd.
公开号:US05686463A1
公开(公告)日:1997-11-11
A class of novel oxadiazoles, substituted on one of the ring carbon atoms with a non-aromatic azacyclic or azabicyclic ring, and substituted on the other ring carbon atom with a substituent of low lipophilicity; are potent muscarinic agonists, and have good CNS penetrability. The compounds are therefore useful in the treatment of neurological and mental illnesses.
Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
申请人:Barth Martine
公开号:US20060178360A1
公开(公告)日:2006-08-10
The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.
本发明涉及新型苯磺酰胺化合物,由公式I和描述所定义,其制备方法及在治疗中的用途。
Pyrazines, pyrimidines and pyridazines useful in the treatment of senile
申请人:Merck Sharp & Dohme Limited
公开号:US05260293A1
公开(公告)日:1993-11-09
The present invention provides pyrazines, pyridazines or pyrimidines, or salts or prodrugs thereof, substituted on one of the ring carbon atoms thereof with a non-aromatic azacyclic or azabicyclic ring system; and independently substituted on each of the other ring carbon atoms with a substituent of low lipophilicity or a hydrocarbon substituent; which compounds stimulate central muscarinic acetylcholine receptors and therefore are useful in the treatment of neurological and mental illnesses.
The Gif oxidation of seven alicyclic tertiary amines leads essentially to the formation of lactams. The structure of the products present in trace amounts supports the mechanistic hypothesis previously advanced. The structures of the oxidation products were investigated using high performance GC-MS system.
Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
申请人:Guyaux Michel
公开号:US20050020660A1
公开(公告)日:2005-01-27
The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention_show high affinities for m3 and/or m2 muscarinic receptors and are particularly suited for treating urinary incontinence.